SequelSEC

Neuronetics, Inc. STIM

Surgical & Medical Instruments & Apparatus · CIK 0001227636 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$41.57M
Fiscal year ended 2026-06-30
Operating income
-$1.50M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Neuronetics, Inc. (STIM) reported revenue of $41.57M and net income of -$3.44M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Neuronetics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Neuronetics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$41.57M$34.45M$41.78M$37.30M$38.11M$31.98M$22.49M$18.53M$16.45M$17.42M
Cost of revenue$20.34M$18.30M$20.07M$20.19M$20.35M$16.24M$7.60M$4.53M$4.27M$4.33M
Gross profit$21.22M$16.15M$21.70M$17.11M$17.76M$15.74M$14.89M$14.00M$12.18M$13.09M
Operating income-$1.50M-$9.00M-$5.04M-$7.32M-$8.06M-$11.01M-$11.47M-$7.73M-$8.51M-$6.86M
Net income-$3.44M-$10.79M-$7.16M-$9.04M-$10.12M-$12.68M-$12.66M-$13.34M-$9.83M-$7.87M
Research & development$1.34M$1.36M$1.67M$1.50M$1.80M$1.62M$5.77M$2.42M$2.24M$2.35M
Weighted-average diluted sharesshares 73.13Mshares 69.59MUnavailableshares 67.31Mshares 66.18Mshares 61.46MUnavailableshares 30.27Mshares 30.05Mshares 29.47M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.05$-0.16Unavailable$-0.13$-0.15$-0.21Unavailable$-0.44$-0.33$-0.27
Selling, general & administrative$21.39M$23.78M$25.08M$22.92M$24.02M$25.14M$20.59M$19.31M$18.45M$17.60M
General & administrative$11.40M$13.05M$13.34M$11.08M$12.15M$13.14M$10.78M$7.44M$6.15M$5.96M
Selling & marketing$9.98M$10.74M$11.74M$11.85M$11.87M$12.00M$9.81M$11.88M$12.30M$11.64M

Balance

Neuronetics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$19.20M$13.21M$28.13M$27.97M$10.97M$20.22M$18.46M$20.87M$42.64M$47.73M
Total assets$131.53M$125.44M$141.55M$145.46M$134.65M$141.99M$140.90M$74.12M$96.81M$103.81M
Current assets$53.23M$47.18M$61.55M$64.89M$56.14M$60.67M$58.12M$53.46M$75.51M$81.86M
Total liabilities$109.89M$108.38M$115.31M$114.10M$103.14M$102.46M$109.10M$64.74M$77.43M$76.16M
Current liabilities$28.31M$28.28M$30.52M$28.94M$27.80M$24.84M$31.26M$16.90M$29.26M$14.50M
Total equity incl. NCI$21.64M$17.06M$26.24M$31.36M$31.51M$39.53M$31.80M$9.38M$19.39M$27.66M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$5.50M$4.72M$4.33M$4.32M$4.94M$4.07M$4.25M$4.96M$6.14M$6.69M
Accounts receivable$15.96M$15.81M$16.47M$18.69M$26.12M$26.20M$23.36M$16.82M$17.14M$17.50M
Goodwill$23.62M$23.62M$23.62M$22.66M$19.08M$18.63M$18.63MUnavailableUnavailableUnavailable
Long-term debt$61.52M$61.30M$65.81M$65.67M$55.54M$55.34M$55.15M$46.00M$46.15M$59.44M
Accounts payable$12.42M$11.43M$10.74M$11.57M$9.72M$8.48M$11.08M$3.30M$4.10M$2.98M

Cash flow

Neuronetics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$1.01M-$9.42M$882.00K-$785.00K-$3.50M-$16.99M-$8.60M-$5.42M-$4.97M-$12.02M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$417.00K-$172.00K-$216.00K-$114.00K-$252.00K-$219.00K-$2.38M$14.00K-$119.00K$68.00K
Financing cash flow$7.41M-$5.58M-$1.03M$17.90M$1.00K$18.98M$9.56MUnavailableUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$688.00K$1.68M$2.18M$1.41M$1.81M$1.44M$1.28M$1.42M$1.56M$1.34M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$400.00K$745.00K$767.00K$500.00K$500.00K$911.00K$446.00K$500.00K$600.00K$560.00K

Derived

Neuronetics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin51.1%46.9%52.0%45.9%46.6%49.2%66.2%75.6%74.0%75.1%
Operating margin-3.6%-26.1%-12.1%-19.6%-21.1%-34.4%-51.0%-41.7%-51.7%-39.4%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue1.7%4.9%5.2%3.8%4.8%4.5%5.7%7.7%9.5%7.7%
Current ratio1.88x1.67x2.02x2.24x2.02x2.44x1.86x3.16x2.58x5.65x
Revenue YoY growth9.1%7.8%85.7%101.3%131.7%83.6%10.7%3.6%-6.6%12.1%
Net margin-8.3%-31.3%-17.1%-24.3%-26.6%-39.6%-56.3%-72.0%-59.8%-45.2%
R&D / revenue3.2%4.0%4.0%4.0%4.7%5.1%25.7%13.0%13.6%13.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity2.84xUnavailable2.51x2.09xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STIM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.